From the William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom.
Hypertension. 2021 Feb;77(2):284-295. doi: 10.1161/HYPERTENSIONAHA.120.14535. Epub 2021 Jan 4.
At the dawn of the new decade, it is judicious to reflect on the boom of knowledge about polygenic risk for essential hypertension supplied by the wealth of genome-wide association studies. Hypertension continues to account for significant cardiovascular morbidity and mortality, with increasing prevalence anticipated. Here, we overview recent advances in the use of big data to understand polygenic hypertension, as well as opportunities for future innovation to translate this windfall of knowledge into clinical benefit.
在新十年的曙光初现之际,反思一下通过大量全基因组关联研究为原发性高血压的多基因风险提供的知识繁荣是明智的。高血压仍然是导致重大心血管发病率和死亡率的主要原因,预计其患病率还会增加。在这里,我们概述了使用大数据来理解多基因高血压的最新进展,以及将这些知识成果转化为临床效益的未来创新机会。